Apr. 24, 2013

 

The Alberta-Pfizer Translational Research Collaboration is receiving new support from Pfizer and the Alberta government to advance leading-edge health care research towards real-world application.

With additional investments from Pfizer of $500,000 and from the Alberta government of $250,000, the Alberta-Pfizer Translational Research Collaboration fund now totals $3.25 million.

“Our collaboration with Pfizer started here at the BIO International Convention, so it’s great to come back to this event and announce our continuing, shared commitment to health research, “ said Thomas Lukaszuk, Deputy Premier and Minister of Enterprise and Advanced Education. “We have the talent and the ideas and strengthening our relationship with a company like Pfizer builds on our province’s capacity to support research excellence that leads to innovative products and services that not only meet the needs of Albertans, but can be marketed worldwide.”

“We are delighted to join the Alberta Ministry of Enterprise and Advanced Education today to announce our continued investment in the Alberta-Pfizer Translational Research Fund,” said John Helou, President, Pfizer Canada Inc. “Alberta has a vibrant and growing medical research and life sciences community and we are pleased to partner with them to help accelerate commercialization of innovative health solutions in Canada.”

“The Alberta-Pfizer Translational Research Collaboration is a great example of how partnerships between government, industry and clinical research can lead to better health care solutions,” said Fred Horne, Minister of Health. “We are working to integrate leading edge health research with health service delivery, ensuring research matches our health system priorities for the benefit of Albertans.”

“We appreciate the ongoing evolution of this powerful partnership and are proud to provide the expertise to ensure support from the fund is directed to outstanding innovation activity. The Alberta/Pfizer Translational Health Opportunities Fund is an example of a visionary partnership that will contribute ultimately to the health and wealth of Albertans,” says Dr. Cy Frank, CEO of Alberta Innovates – Health Solutions.

On November 15, 2011, the Alberta government, Alberta Innovates – Health Solutions (AIHS) and Pfizer signed the Alberta-Pfizer Research Collaboration Agreement. The agreement formalized collaboration between Alberta’s innovation system and Pfizer. The Alberta-Pfizer collaboration is administered by Alberta Innovates – Health Solutions, which oversees the independent, peer-review project selection process.

The collaboration supports health research in a wide variety of disciplines including one promising project to identify which cancer patients will develop a resistance to certain chemotherapy drugs.

The BIO International Convention is the world’s largest convention for biotechnology industries, including pharmaceuticals. Now in its 20th year, BIO will be attended by more than 16,000 industry and public sector decision-makers from more than 60 countries.

Our government was elected to keep building Alberta, to live within its means and to fight to open new markets for Alberta’s resources. We will continue to deliver the responsible change Albertans voted for.

Media inquiries

Earl McKenzie
Public Affairs Officer, Enterprise and Advanced Education
780-415-0891
earl.mckenzie@gov.ab.ca

Lisa Ross
Senior Manager, Corporate Communications, Pfizer Canada
1-866-973-4937
Lisa.Ross@pfizer.com

Eldon McIlwain
Executive Assistant to the Minister of Enterprise and Advanced Education
780-638-1304
eldon.mcilwain@gov.ab.ca

Bart Johnson
Press Secretary, Office of the Minister of Health
780-427-3665
bart.johnson@gov.ab.ca

To call toll free within Alberta dial 310-0000.
Government of Alberta newsroom

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn